Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Bae, Myoung Nam ^a   Kim, Su Hyun ^b   Kim, Young Ok ^a   Jin, Dong Chan ^a   Song, Ho Chul ^a   Choi, Euy Jin ^a   Kim, Yong Lim ^c   Kim, Yon Su ^d   Kang, Shin Wook ^e   Kim, Nam Ho ^f   Yang, Chul Woo ^a   Kim, Yong Kyun ^a  

^a The Catholic University of Korea   (South Korea)

^b Chung Ang University   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG HYPORESPONSIVENESS; DRUG MEGADOSE; DRUG RESPONSE; END STAGE RENAL DISEASE; ERYTHROPOIETIN RESISTANT INDEX; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PHARMACOLOGICAL PARAMETERS; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; AGED; ANEMIA; CHEMISTRY; COMPLICATION; HEMODIALYSIS; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK; SOUTH KOREA; TREATMENT OUTCOME;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RENAL DIALYSIS; REPUBLIC OF KOREA; RISK; TREATMENT OUTCOME;

EID: 84957572357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143348     Document Type: Article

References (28)

1. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 755-62. doi: 10. 2215/CJN.02730608 PMID: 19339417
2. Frank H, Heusser K, Hoffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int. 2004; 66: 832-40. PMID: 15253740
3. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 1992; 124: 424-7. PMID: 1386184
4. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet. 1990; 335: 489-93. PMID: 1968526
5. Chung S, Song HC, Shin SJ, Ihm SH, Park CS, Kim HY, et al. Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodial Int. 2012; 16: 181-7. doi: 10.1111/j.1542-4758.2011.00644.x PMID: 22103889
6. Cotter DJ, Stefanik K, Zhang Y, Thamer M. Improved survival with higher hematocrits: where is the evidence? Semin Dial. 2004; 17: 181-3. PMID: 15144538
7. Sklar AH, Narsipur S. Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin. N Engl J Med. 1998; 339: 2023; author reply-4. PMID: 9882204
8. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008: S75-81. doi: 10.1038/ki.2008.523 PMID: 19034333
9. Kaysen GA, Muller HG, Ding J, Chertow GM. Challenging the validity of the EPO index. Am J Kidney Dis. 2006; 47: 166. PMID: 16377397
10. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363: 1146-55. doi: 10.1056/NEJMoa1005109 PMID: 20843249
11. Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, et al. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study. Int Urol Nephrol. 2014; 46: 151-9. doi: 10.1007/s11255-013-0494-z PMID: 23807369
12. Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012; 59: 108-16. doi: 10.1053/j.ajkd.2011.07.014 PMID: 21890255
13. Korbet SM. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int Suppl. 1993; 40: S111-9. PMID: 8445832
14. De Paepe MB, Schelstraete KH, Ringoir SM, Lameire NH. Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int. 1983; 23: 744-8. PMID: 6876570
15. Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, et al. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol. 2003; 16: 697-702. PMID: 14733416
16. Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol. 2013; 14: 200. doi: 10.1186/1471-2369-14-200 PMID: 24066978
17. Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP, et al. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol. 2012; 35: 198-208. doi: 10.1159/000335685 PMID: 22286821
18. Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, Bradbury BD, et al. Trends in Anemia Management Practices in Patients Receiving Hemodialysis and Peritoneal Dialysis: A Retrospective Cohort Analysis. Am J Nephrol. 2015; 41: 354-61. doi: 10.1159/000431335 PMID: 26107376
19. McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010; 78: 215-23. doi: 10. 1038/ki.2010.108 PMID: 20428102
20. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006; 48 Suppl 1: S2-90. PMID: 16813990
21. Blake PG, Bargman JM, Brimble KS, Davison SN, Hirsch D, McCormick BB, et al. Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Perit Dial Int. 2011; 31: 218-39. doi: 10.3747/pdi.2011.00026 PMID: 21427259
22. Kim YK, Kim SH, Kim HW, Kim YO, Jin DC, Song HC, et al. The association between body mass index and mortality on peritoneal dialysis: a prospective cohort study. Perit Dial Int. 2014; 34: 383-9. doi: 10. 3747/pdi.2013.00008 PMID: 24584607
23. Rao A, Gilg J, Williams A. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses. Nephron Clin Pract. 2013; 125: 183-208. doi: 10.1159/000360029 PMID: 24662174
24. Al-Hilali N, Al-Humoud H, Ninan VT, Nampoory MR, Puliyclil MA, Johny KV. Does parathyroid hormone affect erythropoietin therapy in dialysis patients? Med Princ Pract. 2007; 16: 63-7. PMID: 17159367
25. Vega A, Ruiz C, Abad S, Quiroga B, Velazquez K, Yuste C, et al. Body composition affects the response to erythropoiesis-stimulating agents in patients with chronic kidney disease in dialysis. Ren Fail. 2014; 36: 1073-7. doi: 10.3109/0886022X.2014.917937 PMID: 24846345
26. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013; 28: 1936-45. doi: 10.1093/ndt/gfs368 PMID: 23045431
27. Locatelli F, Pozzoni P, Vecchio LD. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag. 2007; 3: 433-9. PMID: 18488073
28. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991; 50: 702-12. PMID: 1752115